Last €22.53 EUR
Change Today +0.01 / 0.04%
Volume 20.0K
AFX On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 1:55 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

carl zeiss meditec ag - br (AFX) Snapshot

Open
€22.64
Previous Close
€22.52
Day High
€22.69
Day Low
€22.45
52 Week High
07/29/13 - €26.10
52 Week Low
03/14/14 - €19.47
Market Cap
1.8B
Average Volume 10 Days
44.9K
EPS TTM
€1.05
Shares Outstanding
81.3M
EX-Date
03/5/14
P/E TM
21.5x
Dividend
€0.45
Dividend Yield
2.00%
Current Stock Chart for CARL ZEISS MEDITEC AG - BR (AFX)

Related News

No related news articles were found.

carl zeiss meditec ag - br (AFX) Related Businessweek News

View More BusinessWeek News

carl zeiss meditec ag - br (AFX) Details

Carl Zeiss Meditec AG operates as a medical technology company worldwide. It operates through Ophthalmic Systems, Surgical Ophthalmology, and Microsurgery segments. The company provides various products and services in the fields of ophthalmology and optometry; neurosurgery; ear, nose, and throat; spine; plastic and reconstructive (P&R); dentistry; gynecology; and oncology. The company’s ophthalmic equipment and systems handle the diagnosis, progress monitoring, treatment, and follow-up treatment of ophthalmic syndromes comprising vision defects (refraction), cataract, glaucoma, and retinal disorders. It also provides ophthalmic implants consisting of intraocular lenses; and disposables. In addition, the company offers visualization products, such as surgical microscopes and loupes for neuro, spine, P&R, and dental surgeries, as well as for ear, nose, and throat surgeries; intraoperative radiation therapy devices to treat various tumors; and colposcopes for gynecological applications. Carl Zeiss Meditec AG serves physicians in various fields and hospitals through a distribution network of 40 sales companies and 100 agencies. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

2,909 Employees
Last Reported Date: 05/10/14
Founded in 2002

carl zeiss meditec ag - br (AFX) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €470.8K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €379.9K
Chief Sales Officer and Member of Management ...
Total Annual Compensation: €393.5K
Compensation as of Fiscal Year 2013.

carl zeiss meditec ag - br (AFX) Key Developments

Carl Zeiss Meditec AG Reports Earnings Results for the Nine Months of Fiscal 2014

Carl Zeiss Meditec AG reported earnings results for the nine months of fiscal 2014. For the nine months, the company revenue of approximately EUR 673.7 million after nine months of 2013/14 based on preliminary data. This corresponds to a growth rate of 3.8% vs. the previous year's level. Earnings before interest and taxes (EBIT) amounted to EUR 92.1 million after nine months of 2013/14. This corresponds to a slight decline of 1.4% vs. the previous year's level. Earnings per share (EPS) after nine months of 2013/14 amounted to EUR 0.71. This corresponds to a decline of approximately 13% vs. the previous year's level. The decline was mainly attributable to a negative result from currency hedging within the third quarter, compared to a markedly positive result from currency hedging in the previous year's quarter.

Carl Zeiss Meditec AG Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 02:00 PM

Carl Zeiss Meditec AG Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 02:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Christian Muller, Chief Financial Officer and Member of Management Board.

Carl Zeiss Meditec AG Reports Earnings Results for the Six Months of Fiscal 2014; Provides Earnings Guidance for the Full Year of 2014

Carl Zeiss Meditec AG reported earnings results for the six months of fiscal 2014. For the six months, the company announced aided by an extraordinarily strong business in Japan, the company managed - in spite of persistently unfavourable currency effects - to recover from the decline in the first quarter. Revenue increased by around 4% year on year, to EUR 461 million; earnings before interest and taxes reached EUR 63.7 million, which is almost the same as the previous year. For the first time, the company has released a forecast for the year as a whole concerning the further course of business, together with the figures for the quarter. The company provided earnings guidance for the full year of 2014. As reported, the company set itself the objective to increase its revenue at least in line with the rate of market growth in the financial year. In terms of a quantitative forecast, the company's management board anticipates a revenue corridor of EUR 910 to 940 million for the financial year as a whole, based on the six-month figures. This equates to growth of between 0.4% and 3.7%. At the same time, the company continues to feel committed to increasing its EBIT margin, which was down slightly compared with the previous year in the first six months, at 13.8%, to 15% by 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFX:GR €22.53 EUR +0.01

AFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ellex Medical Lasers Ltd A$0.37 AUD 0.00
Iridex Corp $7.85 USD +0.18
Lightpath Technologies Inc $1.23 USD +0.01
Synergetics USA Inc $3.10 USD +0.02
Topcon Corp ¥2,378 JPY +12.00
View Industry Companies
 

Industry Analysis

AFX

Industry Average

Valuation AFX Industry Range
Price/Earnings 19.6x
Price/Sales 1.9x
Price/Book 2.6x
Price/Cash Flow 19.8x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARL ZEISS MEDITEC AG - BR, please visit www.meditec.zeiss.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.